ALNYLAM PHARMACEUTICALS, INC. Basic Shares Outstanding (Weighted Average)
ALNYLAM PHARMACEUTICALS, INC. (ALNY) reported Basic Shares Outstanding (Weighted Average) of 133.61 million shares for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:WeightedAverageNumberOfSharesOutstandingBasic · last filed 2026-07-30
- ALNYLAM PHARMACEUTICALS, INC. weighted average number of shares outstanding, basic for the quarter ending 2026-06-30 was 133.61M shares, a 2.28% increase year-over-year.
- ALNYLAM PHARMACEUTICALS, INC. weighted average number of shares outstanding, basic for the quarter ending 2025-12-31 was 132.25M shares, a 2.42% increase year-over-year.
- ALNYLAM PHARMACEUTICALS, INC. weighted average number of shares outstanding, basic for the quarter ending 2025-09-30 was 131.45M shares, a 2.22% increase year-over-year.
- ALNYLAM PHARMACEUTICALS, INC. weighted average number of shares outstanding, basic for the quarter ending 2025-06-30 was 130.63M shares, a 3.07% increase year-over-year.
- ALNYLAM PHARMACEUTICALS, INC. weighted average number of shares outstanding, basic for fiscal 2025 was 131.00M shares, a 2.63% increase from fiscal 2024.
- ALNYLAM PHARMACEUTICALS, INC. weighted average number of shares outstanding, basic for fiscal 2024 was 127.65M shares, a 2.20% increase from fiscal 2023.
- ALNYLAM PHARMACEUTICALS, INC. weighted average number of shares outstanding, basic for fiscal 2023 was 124.91M shares, a 2.64% increase from fiscal 2022.
- ALNYLAM PHARMACEUTICALS, INC. weighted average number of shares outstanding, basic for fiscal 2022 was 121.69M shares, a 2.73% increase from fiscal 2021.
| Period end | Weighted Average Number of Shares Outstanding, Basic 3 month | Weighted Average Number of Shares Outstanding, Basic 6 month | Weighted Average Number of Shares Outstanding, Basic 9 month | Weighted Average Number of Shares Outstanding, Basic 12 month |
|---|---|---|---|---|
| 2026-06-30 | 133.61M shares 10-Q · filed 2026-07-30 | 133.24M shares 10-Q · filed 2026-07-30 | ||
| 2025-12-31 | 132.25M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | 131.85M shares derived: average of 2 quarters · filed 2026-02-12 | 131.44M shares derived: average of 3 quarters · filed 2026-07-30 | 131.00M shares 10-K · filed 2026-02-12 |
| 2025-09-30 | 131.45M shares 10-Q · filed 2025-10-30 | 131.04M shares derived: average of 2 quarters · filed 2026-07-30 | 130.59M shares 10-Q · filed 2025-10-30 | 130.22M shares derived: average of 4 quarters · filed 2026-07-30 |
| 2025-06-30 | 130.63M shares 10-Q · filed 2026-07-30 | 130.16M shares 10-Q · filed 2026-07-30 | 129.81M shares derived: average of 3 quarters · filed 2026-07-30 | 129.51M shares derived: average of 4 quarters · filed 2026-07-30 |
| 2025-03-31 | 129.68M shares 10-Q · filed 2025-05-01 | 129.40M shares derived: average of 2 quarters · filed 2026-02-12 | 129.13M shares derived: average of 3 quarters · filed 2026-02-12 | 128.53M shares derived: average of 4 quarters · filed 2026-02-12 |
| 2024-12-31 | 129.13M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | 128.86M shares derived: average of 2 quarters · filed 2026-02-12 | 128.15M shares derived: average of 3 quarters · filed 2026-02-12 | 127.65M shares 10-K · filed 2026-02-12 |
| 2024-09-30 | 128.59M shares 10-Q · filed 2025-10-30 | 127.66M shares derived: average of 2 quarters · filed 2025-10-30 | 127.16M shares 10-Q · filed 2025-10-30 | 126.77M shares derived: average of 4 quarters · filed 2026-02-12 |
| 2024-06-30 | 126.73M shares 10-Q · filed 2025-07-31 | 126.44M shares 10-Q · filed 2025-07-31 | 126.16M shares derived: average of 3 quarters · filed 2026-02-12 | 125.93M shares derived: average of 4 quarters · filed 2026-02-12 |
| 2024-03-31 | 126.14M shares 10-Q · filed 2025-05-01 | 125.88M shares derived: average of 2 quarters · filed 2026-02-12 | 125.66M shares derived: average of 3 quarters · filed 2026-02-12 | 125.41M shares derived: average of 4 quarters · filed 2026-02-12 |
| 2023-12-31 | 125.62M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | 125.42M shares derived: average of 2 quarters · filed 2026-02-12 | 125.17M shares derived: average of 3 quarters · filed 2026-02-12 | 124.91M shares 10-K · filed 2026-02-12 |
| 2023-09-30 | 125.22M shares 10-Q · filed 2024-10-31 | 124.94M shares derived: average of 2 quarters · filed 2024-10-31 | 124.67M shares 10-Q · filed 2024-10-31 | 124.32M shares derived: average of 4 quarters · filed 2025-02-13 |
| 2023-06-30 | 124.66M shares 10-Q · filed 2024-08-01 | 124.39M shares 10-Q · filed 2024-08-01 | 124.02M shares derived: average of 3 quarters · filed 2025-02-13 | 123.55M shares derived: average of 4 quarters · filed 2025-02-13 |
| 2023-03-31 | 124.11M shares 10-Q · filed 2024-05-02 | 123.70M shares derived: average of 2 quarters · filed 2025-02-13 | 123.19M shares derived: average of 3 quarters · filed 2025-02-13 | 122.61M shares derived: average of 4 quarters · filed 2025-02-13 |
| 2022-12-31 | 123.28M shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-13 | 122.72M shares derived: average of 2 quarters · filed 2025-02-13 | 122.11M shares derived: average of 3 quarters · filed 2025-02-13 | 121.69M shares 10-K · filed 2025-02-13 |
| 2022-09-30 | 122.17M shares 10-Q · filed 2023-11-02 | 121.53M shares derived: average of 2 quarters · filed 2023-11-02 | 121.16M shares 10-Q · filed 2023-11-02 | 120.81M shares derived: average of 4 quarters · filed 2024-02-15 |
| 2022-06-30 | 120.90M shares 10-Q · filed 2023-08-03 | 120.65M shares 10-Q · filed 2023-08-03 | 120.36M shares derived: average of 3 quarters · filed 2024-02-15 | 120.05M shares derived: average of 4 quarters · filed 2024-02-15 |
| 2022-03-31 | 120.39M shares 10-Q · filed 2023-05-04 | 120.09M shares derived: average of 2 quarters · filed 2024-02-15 | 119.77M shares derived: average of 3 quarters · filed 2024-02-15 | 119.27M shares derived: average of 4 quarters · filed 2024-02-15 |
| 2021-12-31 | 119.79M shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-15 | 119.47M shares derived: average of 2 quarters · filed 2024-02-15 | 118.90M shares derived: average of 3 quarters · filed 2024-02-15 | 118.45M shares 10-K · filed 2024-02-15 |
| 2021-09-30 | 119.14M shares 10-Q · filed 2022-10-27 | 118.46M shares derived: average of 2 quarters · filed 2022-10-27 | 118.00M shares 10-Q · filed 2022-10-27 | 117.57M shares derived: average of 4 quarters · filed 2023-02-23 |
| 2021-06-30 | 117.77M shares 10-Q · filed 2022-07-28 | 117.43M shares 10-Q · filed 2022-07-28 | 117.04M shares derived: average of 3 quarters · filed 2023-02-23 | 116.78M shares derived: average of 4 quarters · filed 2023-02-23 |
| 2021-03-31 | 117.08M shares 10-Q · filed 2022-04-28 | 116.68M shares derived: average of 2 quarters · filed 2023-02-23 | 116.45M shares derived: average of 3 quarters · filed 2023-02-23 | 116.06M shares derived: average of 4 quarters · filed 2023-02-23 |
| 2020-12-31 | 116.28M shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | 116.13M shares derived: average of 2 quarters · filed 2023-02-23 | 115.73M shares derived: average of 3 quarters · filed 2023-02-23 | 114.99M shares 10-K · filed 2023-02-23 |
| 2020-09-30 | 115.99M shares 10-Q · filed 2021-10-28 | 115.45M shares derived: average of 2 quarters · filed 2021-10-28 | 114.55M shares 10-Q · filed 2021-10-28 | |
| 2020-06-30 | 114.91M shares 10-Q · filed 2021-08-03 | 113.83M shares 10-Q · filed 2021-08-03 | ||
| 2019-12-31 | 109.26M shares 10-K · filed 2022-02-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |